|
||
© The Rockefeller University Press,
0021-9525/2000//1005 $5.00
The Journal of Cell Biology, Volume 149, Number 5,
, 2000 1005-1010
Brief Report |
Jil-1, a Chromosomal Kinase Implicated in Regulation of Chromatin Structure, Associates with the Male Specific Lethal (Msl) Dosage Compensation Complex
kristen{at}iastate.edu
JIL-1 is a novel chromosomal kinase that is upregulated almost twofold on the male X chromosome in Drosophila. Here we demonstrate that JIL-1 colocalizes and physically interacts with male specific lethal (MSL) dosage compensation complex proteins. Furthermore, ectopic expression of the MSL complex directed by MSL2 in females causes a concomitant upregulation of JIL-1 to the female X that is abolished in msl mutants unable to assemble the complex. Thus, these results strongly indicate JIL-1 associates with the MSL complex and further suggests JIL-1 functions in signal transduction pathways regulating chromatin structure.
Key Words: protein kinase dosage compensation Drosophila chromatin MSL complex
© 2000 The Rockefeller University Press
| Introduction |
|---|
|
|
|---|
In an effort to determine the molecular basis for dosage compensation in Drosophila, a number of genetic screens were performed that have identified several genes necessary for achieving equal levels of most X-linked transcription (Fukunaga et al. 1975; Belote and Lucchesi 1980). The products of these genes assemble into a complex termed MSL (male specific lethal) that is thought to be responsible for targeting a histone acetyltransferase that acetylates histone H4 (H4Ac16) to the upregulated male X chromosome, which in turn leads to altered chromatin structure (Smith et al. 2000). The MSL holocomplex is known to include MSL1, a novel acidic protein (Palmer et al. 1993); MSL2, a RING finger protein (Bashaw and Baker 1995; Kelley et al. 1995; Zhou et al. 1995); MSL3, a chromodomain protein (Gorman et al. 1995); MLE, an RNA helicase (Kuroda et al. 1991); MOF, a histone acetyltransferase (Hilfiker et al. 1997); and two nontranslated RNAs, roX1 and roX2 (Meller et al. 1997; Franke and Baker 1999). The MSL complex preferentially associates at hundreds of sites on the male X but fails to assemble in females due to a Sex lethal–regulated block in translation of the MSL2 subunit (reviewed in Bashaw and Baker 1996). The MSL complex colocalizes with the H4Ac16 pattern on the male X chromosome, and absence of any of the MSL complex subunits prevents both MSL complex assembly as well as the enhanced H4Ac16 modification on the male X chromosome (Turner et al. 1992; Bone et al. 1994). Furthermore, studies have shown that ectopic expression of MSL2 in females results in formation and targeting of the MSL complex to both female X chromosomes with a concomitant upregulation of H4Ac16 levels (Kelley et al. 1995; Bashaw and Baker 1995).
Thus, in order to understand the mechanisms of dosage compensation occurring in Drosophila it is necessary to identify all the components of the MSL complex and to determine how they may interact to mediate upregulation of transcription on the male X. Recently, we have characterized a novel tandem kinase, JIL-1, which is enriched almost twofold on the male larval polytene X-chromosome (Jin et al. 1999). In this study, we demonstrate (a) that JIL-1 colocalizes with the MSL complex proteins on the male X, (b) that JIL-1 can molecularly interact with MSL complex proteins, (c) that ectopic expression of MSL2 in females causes a concomitant upregulation of JIL-1 to the female X, and (d) that this upregulation is abolished in msl mutants that are unable to assemble the complex. Thus, these results strongly indicate that JIL-1 can associate with the MSL dosage compensation complex. The ability of JIL-1 to phosphorylate histone H3 in vitro (Jin et al. 1999) further suggests a model where JIL-1's role in the MSL complex is to assist in regulating transcription possibly through modification of chromatin.
| Materials and Methods |
|---|
|
|
|---|
Immunohistochemistry
Anti–JIL-1 IgY antibodies were purified from eggs of chickens (Aves Labs) that had been injected with pGEXFI, a GST (glutathione-S-transferase)–JIL-1 fusion protein containing residues 886–1,013 (Jin et al. 1999). A JIL-1–specific monoclonal antibody, 5C9, was made to pGEXFI using standard procedures (Harlow and Lane 1988). Affinity-purified anti-MSL1 (rabbit), -MSL2 (rabbit), and -MSL3 (goat) antibodies were the generous gift of Drs. M. Kuroda and R. Kelley. Polytene chromosome squash preparations from late third instar larvae were double immunostained using FITC- and TRITC-conjugated species-specific secondary antibodies as previously described by Jin et al. 1999.
Confocal microscopy was performed with a Leica confocal TCS NT microscope system equipped with separate Argon-UV, Argon, and Krypton lasers and the appropriate filter sets for Hoechst, FITC, and TRITC imaging. A separate series of confocal images for each fluorophor of double labeled preparations was obtained simultaneously with z intervals of typically 0.5 µm. An average projection image for each of the image stacks was obtained using the NIH-image software. These were subsequently imported into Photoshop where they were pseudocolored, image processed, and merged.
JIL-1 Fusion Protein Constructs
An inducible full-length JIL-1 fusion protein with COOH-terminal V5 and His6 tags for expression in S2 cells was constructed by site-directed mutagenesis using the Transformer kit (CLONTECH Laboratories, Inc.) and inserted into the pMT/V5-His6 B vector (Invitrogen). The resulting construct was verified by sequencing and stably transformed into S2 cells using standard procedures for transfection and S2 cell line culture (Invitrogen).
A nearly full-length GST–JIL-1 fusion protein (residues 34–1,207) as well as various truncated GST–JIL-1 fusion proteins were constructed by PCR and inserted into the pGEX4T-2 (Amersham Pharmacia) vector for expression in E. coli. The following four truncated GST–JIL-1 fusion proteins were made: NTD (residues 1–211), KDI (residues 251–554), KDII (residues 615–917), and CTD (residues 927–1,207). The GST fusion protein constructs were verified by sequencing and fusion proteins purified using glutathione agarose beads (Sigma-Aldrich) following standard protocols (Amersham Pharmacia).
Coimmunoprecipitation and In Vitro Protein Interaction Assays
For immunoprecipitation (ip) experiments with V5-tagged JIL-1, 3 µg anti-V5 monoclonal antibody (Invitrogen) was coupled with 5 µl protein G–Sepharose beads (Amersham Pharmacia) for 2 h at 4°C on a rotating wheel in 50 µl ip buffer (20 mM Tris-HCl, 150 mM NaCl, 10 mM EDTA, 1 mM EGTA, 0.2% Triton X-100, 0.2% NP-40, 2 mM Na3VO4, 1 mM PMSF and 1.5 µg/ml aprotinin, pH 8.0) and then incubated overnight at 4°C with S2 cell lysate (106 cells/200 µl ip buffer) from cells stably expressing a V5–JIL-1 fusion protein or from control cells not expressing V5–JIL-1. For coimmunoprecipitation experiments with MSL proteins, 1 µg anti-MSL1, 1 µg anti-MSL2, 2 µg anti-MSL3, or identical amounts of the appropriate control antibodies (rabbit preimmune sera or normal goat sera from GIBCO BRL) were coupled with 5 µl protein G–Sepharose beads (Amersham Pharmacia) for 2 h at 4°C on a rotating wheel in 50 µl ip buffer. S2 cell lysate from V5–JIL-1–expressing cells was prepared in ip buffer (106 cells/200 µl ip buffer) and precleared with 5 µl normal sera and 20 µl protein G beads for 2 h at 4°C. The precleared lysate and protein G beads preloaded with the appropriate antibody were combined and incubated overnight at 4°C with continuous mixing. Beads were then washed four times for 10 min each with 1 ml of ip buffer. The resulting immunocomplexes were analyzed by SDS-PAGE and Western blotting according to standard techniques as described in Jin et al. 1999. In some experiments, endogenous JIL-1 and MSL proteins were immunoprecipitated from lysate of untransfected S2 cells using the same procedure. For in vitro protein–protein interaction assays,
0.5 µg of GST or the appropriate GST fusion protein were coupled with glutathione agarose beads and incubated with 300 µl of S2 cell lysate (from
106 cells) at 4°C for 6 h on a rotating wheel. The beads were washed 4 times for 10 min each with 1 ml ip buffer, and proteins retained on the glutathione agarose beads were analyzed by SDS-PAGE and Western blotting with signals detected by ECL chemiluminescence (Amersham Pharmacia).
| Results |
|---|
|
|
|---|
|
|
|
|
| Discussion |
|---|
|
|
|---|
The MSL complex is believed to promote dosage compensation in males by targeting MOF, the histone acetylase responsible for the increased H4Ac16 modification found on the male X chromosome (Smith et al. 2000). This modification is thought to lead to a more diffuse chromatin structure and enhanced accessibility of the DNA for transcription. However, it is becoming increasingly evident that in addition to acetylation, phosphorylation may also play a key role not only at the level of modulation of transcription factor activity, but also more generally at the level of chromatin structure. For example, histone H3 phosphorylation has been found to occur in a small subset of nucleosomes in mitogenically stimulated cells (Barratt et al. 1994; Sassone-Corsi et al. 1999). This phosphorylation appears to be regulated by mitogen-activated signal transduction cascades indicating a direct link between signal transduction pathways and chromatin structure. JIL-1 has been shown to phosphorylate histone H3 in vitro (Jin et al. 1999) suggesting that the MSL complex may affect chromatin structure not only by histone acetylation, but also by histone phosphorylation. However, the finding that JIL-1 interacts with the MSL complex through its kinase domains also raises the possibility that one or more of the proteins in the MSL complex itself could be a substrate for JIL-1. Regardless of whether the substrate(s) for JIL-1 is histones or components of the MSL complex or both it is likely that the JIL-1 kinase serves as a regulator of MSL complex function through site-specific phosphorylation.
The finding that JIL-1 associates with the MSL complex is based on physical interaction assays such as coimmunoprecipitation and GST pull-down experiments. These approaches require a fairly stable interaction between JIL-1 and the MSL complex making it unlikely that this association depends on the presence of the roX RNAs. This is in contrast to the MLE product that is not found as part of the MSL complex during chromatographic separation (Copps et al. 1998), a finding consistent with it being the only one of the known MSL complex proteins to be lost from the male X chromosomes upon treatment with RNase (Richter et al. 1996). Moreover, the finding that addition of GST–JIL-1 fusion protein to S2 cell extracts can be used to pull down the MSL complex indicates that this association can occur in vitro and suggests that the JIL-1 kinase can interact with the preassembled MSL complex. However, since this preassembled complex may already contain endogenous JIL-1 it does not address whether the formation of the MSL complex requires the presence of JIL-1 protein or whether JIL-1 is present in the MSL complex in stoichiometric amounts.
In contrast to the other MSL complex proteins, JIL-1 is also present in female chromosomes and male autosomes (Jin et al. 1999), all of which are void of MSL complexes (Bashaw and Baker 1996). Future experiments will determine whether JIL-1's more general distribution on the autosomes and on the female X chromosomes may reflect JIL-1's participation in other transcriptional regulator complexes. The deployment of certain proteins into several different chromatin remodeling complexes is emerging as a common theme in the composition of various chromatin remodeling machines and may be a way to accomplish hierarchical levels of gene regulation (Holstege et al. 1998). Here we have shown that JIL-1 associates with at least one known chromatin remodeling machine, the MSL complex, suggesting a direct link between the JIL-1 kinase and the signal transduction pathways regulating transcription and chromatin structure.
| Acknowledgments |
|---|
This work was supported by NSF Grant MCB-9600587.
Submitted: 6 March 2000
Revised: 19 April 2000
Accepted: 24 April 2000
The first two authors contributed equally to this work.
| References |
|---|
|
|
|---|
Baker B.S., Gorman M. & Marin I.. Dosage compensation in Drosophila, Annu. Rev. Genet., 28, 1994, 491–521.[Medline]
Barratt M.J., Hazzalin C.A., Cano E. & Mahadevan L.C.. Mitogen-stimulated phosphorylation of histone H3 is targeted to a small hyperacetylation-sensitive fraction, Proc. Natl. Acad. Sci. USA., 91, 1994, 4781–4785.
Bashaw G.J. & Baker B.S.. The msl-2 dosage compensation gene of Drosophila encodes a putative DNA-binding protein whose expression is sex specifically regulated by Sex-lethal, Development., 121, 1995, 3245–3258.[Abstract]
Bashaw G.J. & Baker B.S.. Dosage compensation and chromatin structure in Drosophila, Curr. Opin. Genet. Dev., 6, 1996, 496–501.[Medline]
Belote J.M. & Lucchesi J.C.. Male-specific lethal mutations of Drosophila melanogaster, Genetics., 96, 1980, 165–186.
Bone J.R., Lavender J., Richman R., Palmer M.J., Turner B.M. & Kuroda M.I.. Acetylated histone H4 on the male X chromosome is associated with dosage compensation in Drosophila, Genes Dev., 8, 1994, 96–104.
Copps K., Richman R., Lyman L.M., Chang K.A., Rampersad-Ammons J. & Kuroda M.I.. Complex formation by the Drosophila MSL proteinsrole of the MSL2 RING finger in protein complex assembly, EMBO (Eur. Mol. Biol. Organ.) J., 17, 1998, 5409–5417.[Medline]
Franke A. & Baker B.S.. The rox1 and rox2 RNAs are essential components of the compensasome, which mediates dosage compensation in Drosophila, Mol. Cell., 4, 1999, 117–122.[Medline]
Fukunaga, A., A. Tanaka, and K. Oishi. 1975. Maleless, a recessive autosomal mutant of Drosophila melanogaster that specifically kills male zygotes. Genetics. 81:135–114.
Gorman M. & Baker B.S.. How flies make one equal twodosage compensation in Drosophila, Trends Gen., 10, 1994, 376–380.[Medline]
Gorman M., Franke A. & Baker B.S.. Molecular characterization of the male-specific lethal-3 gene and investigation of the regulation of dosage compensation in Drosophila, Development., 121, 1995, 463–475.[Abstract]
Harlow E. & Lane D., AntibodiesA Laboratory Manual, 1988, Cold Spring Harbor Laboratory Press, , Cold Spring Harbor, NY.
Hilfiker A., Hilfiker-Kleiner D., Pannuti A. & Lucchesi J.C.. mof, a putative acetyl transferase gene related to the Tip60 and MOZ human genes and to the SAS genes of yeast, is required for dosage compensation in Drosophila, EMBO (Eur. Mol. Biol. Organ.) J., 16, 1997, 2054–2060.[Medline]
Holstege F.C., Jennings E.G., Wyrick J.J., Lee T.I., Hengartner C.J., Green M.R., Golub T.R., Lander E.S. & Young R.A.. Dissecting the regulatory circuitry of a eukaryotic genome, Cell., 95, 1998, 717–728.[Medline]
Jin Y., Wang Y., Walker D.L., Dong H., Conley C., Johansen J. & Johansen K.M.. JIL-1a novel chromosomal tandem kinase implicated in transcriptional regulation in Drosophila, Mol. Cell., 4, 1999, 129–135.[Medline]
Kelley R.L. & Kuroda M.I.. Equality for X chromosomes, Science., 270, 1995, 1607–1610.
Kelley R.L., Solovyeva I., Lyman L.M., Richman R., Solovyev V. & Kuroda M.I.. Expression of msl-2 causes assembly of dosage compensation regulators on the X chromosomes and female lethality in Drosophila, Cell., 81, 1995, 867–877.[Medline]
Kuroda M.I., Kernan M.J., Kreber R., Ganetzky B. & Baker B.S.. The maleless protein associates with the X chromosome to regulate dosage compensation in Drosophila, Cell., 66, 1991, 935–947.[Medline]
Lucchesi J.C.. Dosage compensation in flies and wormsthe ups and downs of X-chromosome regulation, Curr. Opin. Genet. Dev., 8, 1998, 179–184.[Medline]
Meller V.H., Wu K.H., Roman G., Kuroda M.I. & Davis R.L.. roX1 RNA paints the X chromosome of male Drosophila and is regulated by the dosage compensation system, Cell., 88, 1997, 445–457.[Medline]
Palmer M.J., Mergner V.A., Richman R., Manning J.E., Kuroda M.I. & Lucchesi J.C.. The male-specific lethal-one (msl-1) gene of Drosophila melanogaster encodes a novel protein that associates with the X chromosome in males, Genetics, 134, 1993, 545–557.[Abstract]
Richter L., Bone J.R. & Kuroda M.I.. RNA-dependent association of the Drosophila maleless protein with the male X chromosome, Genes Cells, 1, 1996, 325–336.[Abstract]
Roberts D.B., Drosophila: A Practical Approach, 1986, IRL Press, , Oxford, UKpp. 295.
Sassone-Corsi P., Mizzen C.A., Cheung P., Crosio C., Monaco L., Jacquot S., Hanauer A. & Allis C.D.. Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3, Science., 285, 1999, 886–891.
Smith E.R., Pannuti A., Gu W., Seurnagel A., Cook R.G., Allis C.D. & Lucchesi J.C.. The Drosophila MSL complex acetylates histone H4 at lysine 16, a chromatin modification linked to dosage compensation, Mol. Cell. Biol., 20, 2000, 312–318.
Turner B.M., Birley A.J. & Lavender J.. Histone H4 isoforms acetylated at specific lysine residues define individual chromosomes and chromatin domains in Drosophila polytene nuclei, Cell., 69, 1992, 375–384.[Medline]
Wolffe A.P. & Hayes J.J.. Chromatin disruption and modification, Nucleic Acids Res., 27, 1999, 711–720.
Zhou S., Yang Y., Scott M.J., Pannuti A., Fehr K.C., Eisen A., Koonin E.V., Fouts D.L., Wrightsman R., Manning J.E. & Lucchesi J.C.. Male-specific lethal 2, a dosage compensation gene of Drosophila, undergoes sex-specific regulation and encodes a protein with a RING finger and a metallothionein-like cysteine cluster, EMBO (Eur. Mol. Biol. Organ.) J., 14, 1995, 2884–2895.[Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|